The development of the PlexiQoL: A patient‐reported outcome measure for adults with neurofibromatosis type 1‐associated plexiform neurofibromas

A Heaney, J Wilburn, M Rouse… - … Genetics & Genomic …, 2020 - Wiley Online Library
Background To develop and validate a patient‐reported outcome (PRO) measure of quality
of life (QoL), specific to patients with Neurofibromatosis Type 1 (NF1)‐associated plexiform …

[HTML][HTML] The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural …

BAE Dhaenens, SA van Dijk, W Taal… - Journal of Patient …, 2024 - Springer
Background Half of the patients with Neurofibromatosis type 1 (NF1) develop one or more
tumours called plexiform neurofibromas, which can have a significant impact on Quality of …

Using a qualitative approach to conceptualize concerns of patients with neurofibromatosis type 1 associated plexiform neurofibromas (pNF) across the lifespan

JS Lai, SE Jensen, ZS Patel… - American journal of …, 2017 - Wiley Online Library
Neurofibromatosis Type 1 (NF1) plexiform neurofibromas (pNFs) are associated with a
variety of symptoms and concerns that affect patients' quality of life (QOL), highlighting the …

[HTML][HTML] Impact of neurofibromatosis type 1 with plexiform neurofibromas on the health-related quality of life and work productivity of adult patients and caregivers in …

HK Yoo, A Porteous, A Ng, K Haria, A Griffiths, A Lloyd… - BMC neurology, 2023 - Springer
Background Plexiform neurofibromas (PN) are complex, benign nerve-sheath tumours that
occur in 30–50% of patients with neurofibromatosis type 1 (NF1), a rare, genetic disorder …

Patient reported outcomes measurement information system and quality of life in neurological disorders measurement system to evaluate quality of life for children and …

JS Lai, SE Jensen, J Charrow, R Listernick - The Journal of pediatrics, 2019 - Elsevier
Objective To assess the health-related quality of life of children with neurofibromatosis type
1-related plexiform neurofibromas (pNF) using a battery of patient-reported outcome …

Lifespan development: symptoms experienced by individuals with neurofibromatosis type 1 associated plexiform neurofibromas from childhood into adulthood

SE Jensen, ZS Patel, R Listernick, J Charrow… - Journal of clinical …, 2019 - Springer
This secondary data analysis qualitatively identified salient concerns reported by individuals
with Neurofibromatosis Type 1 (NF1)-associated plexiform neurofibromas (pNFs) at different …

A qualitative study of the impact of plexiform neurofibromas on need fulfilment in adults with neurofibromatosis type 1

A Heaney, J Wilburn, S Langmead… - SAGE Open …, 2019 - journals.sagepub.com
Objective: To explore the impact of plexiform neurofibromas on the lives of adults with
neurofibromatosis type 1. Background: Neurofibromatosis type 1 is a complex neurogenetic …

Development of the pediatric quality of life inventory neurofibromatosis type 1 module items for children, adolescents and young adults: qualitative methods

K Nutakki, JW Varni, S Steinbrenner… - Journal of Neuro …, 2017 - Springer
Health-related quality of life (HRQOL) is arguably one of the most important measures in
evaluating effectiveness of clinical treatments. At present, there is no disease-specific …

Current recommendations for patient-reported outcome measures assessing domains of quality of life in neurofibromatosis clinical trials

PL Wolters, AM Vranceanu, HL Thompson, S Martin… - Neurology, 2021 - AAN Enterprises
Objective To review and recommend patient-reported outcome (PRO) measures assessing
multidimensional domains of quality of life (QoL) to use as clinical endpoints in medical and …

The NFTI-QOL: a disease-specific quality of life questionnaire for neurofibromatosis 2

RE Hornigold, JF Golding, G Leschziner… - … Surgery Part B: Skull …, 2012 - thieme-connect.com
The objective of this study was to develop a reliable, validated disease-specific score
measuring quality of life (QOL) in clinical practice and treatment trials in Neurofibromatosis 2 …